Your browser doesn't support javascript. This means that the content or functionality of our website will be limited or unavailable. If you need more information about Vinnova, please contact us.

Our e-services for applications, projects and assessments close on Thursday 25 April at 4:30pm because of system upgrades. We expect to open them again on Friday 26 April at 8am the latest.

Development of a protein biomarker test for preoperative diagnosis of ovarian cancer.

Reference number
Coordinator Uppsala universitet - Institutionen för immunologi, genetik och patologi
Funding from Vinnova SEK 2 312 500
Project duration October 2017 - October 2019
Status Completed

Purpose and goal

The goal of the project is to improve ovarian cancer diagnostics by developing a biomarker test that can be used to determine if women with a pelvic aberrant ultrasound need to undergo surgical diagnostics.

Expected results and effects

The project has resulted in a test based on the protein profile in a blood test that can be used to assess whether a deviating ultrasound is of a benign nature and does not require surgical diagnostics or requires surgery. The results are very promising, and the test will be offered by selected service laboratories.

Planned approach and implementation

The project is based on a collaboration between two universities and healthcare regions as well as a biotechnology company (Olink), with a unique technology for protein analysis. In a number of subprojects we have identified a protein profile that can be used, developed this into a test with absolute quantification, applied for a patent for this, and conducted a clinical study to show its value. The project is based on the utilization of expertise and resources from the three participating organizations.

The project description has been provided by the project members themselves and the text has not been looked at by our editors.

Last updated 8 January 2019

Reference number 2017-03586

Page statistics